Minor Use Minor Species Development of Drugs (R01)
ID: 354573Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354573

Additional Information

https://grants.nih.gov/grants/guide/pa-files/PAR-24-216.html
Timeline
    Description

    The Food and Drug Administration (FDA) is inviting applications for the Minor Use Minor Species Development of Drugs (R01) grant, aimed at supporting the development of new animal drugs for minor uses in major species or any uses in minor species. Eligible applicants must have an active Investigational New Animal Drug (INAD) file with the FDA and must hold a minor use or minor species designation for the drug under investigation, ensuring compliance with regulatory standards. This initiative underscores the FDA's commitment to enhancing veterinary drug development for underserved markets, with grants providing up to $250,000 annually for one-year projects, potentially extendable for long-term studies. Interested parties should submit their applications by the specified deadlines, with the next due date on July 29, 2024, and can contact Terrin Brown at terrin.brown@fda.hhs.gov for further information.

    Point(s) of Contact
    terrin.brown@fda.hhs.gov
    Files
    Title
    Posted
    PAR-24-216.html
    The Notice of Funding Opportunity (NOFO) from the Department of Health and Human Services, specifically from the U.S. Food and Drug Administration (FDA), invites applications for the development of new animal drugs under the Minor Use Minor Species (MUMS) program. This program aims to support research through R01 Research Project Grants for drugs intended for minor uses in major species or any uses in minor species. Eligible applicants must have an active Investigational New Animal Drug (INAD) file with the FDA and meet designated requirements prior to application submission. The funding opportunity spans from May 3, 2024, with application due dates extending into 2027. Each grant may support one-year projects with direct costs not exceeding $250,000 annually, potentially extending to three years for long-term studies. A thorough review will evaluate the scientific merit of proposals based on significance, investigator capabilities, methodology, and environment of the proposed research. Compliance with regulatory standards and submission requirements is mandatory, ensuring rigorous oversight for research involving animal subjects. The initiative signifies the FDA's commitment to enhancing veterinary drug development for underserved markets while adhering to comprehensive safety and efficacy evaluations.
    Similar Opportunities
    Minor Use Minor Species Development of Drugs (R01)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the development of drugs for minor uses in major species or for use in minor species through its Minor Use Minor Species Development of Drugs (R01) grant program. This initiative aims to support research projects that assist in the safety and effectiveness testing of new animal drugs designated for minor uses, with a focus on entities that have opened an Investigational New Animal Drug (INAD) file and received the necessary designations from the FDA's Office of Minor Use and Minor Species Animal Drug Development. The program is crucial for enhancing veterinary care options for less common animal species, ensuring that these drugs meet FDA approval standards. Interested applicants can apply for grants with a funding ceiling of $250,000, with an expected six awards available for the fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at (240) 402-7610.
    Animal and Veterinary Innovation Centers (U18)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for the Animal and Veterinary Innovation Centers (U18) funding opportunity, aimed at establishing long-term partnerships to address critical research areas in veterinary medicine. This initiative focuses on driving research to prevent and control Highly Pathogenic Avian Influenza (HPAI), advancing regulatory science for intentional genomic alterations in animals, and developing veterinary products for underrepresented species and conditions. With an estimated total program funding of $3 million and awards of up to $1.25 million available, applications are due by August 5, 2024. Interested applicants, particularly higher education institutions serving minority populations, can find more information and submission guidelines at the provided link or contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Vet-LIRN Capacity-Building Project and Equipment Grants (U18)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Vet-LIRN Capacity-Building Project and Equipment Grants (U18) to enhance the capabilities of veterinary diagnostic laboratories within the Vet-LIRN network. This funding opportunity aims to support projects focused on animal food safety, antimicrobial resistance, and surveillance efforts related to foodborne illnesses and emerging diseases, including COVID-19. The initiative is part of the FDA's commitment to improving food safety standards and aligns with the Food Safety Modernization Act, emphasizing the importance of federal involvement in bolstering food safety and containment capabilities. Interested applicants, including small businesses and various institutions, can apply for grants ranging from $225,000 to $2.5 million, with applications accepted annually until September 4, 2028. For further details, contact Kimberly Pendleton at kimberly.pendleton@fda.hhs.gov or visit the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-202.html.
    Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Animal Food Regulatory Program Standards Implementation Development and Maintenance," aimed at enhancing state animal food regulatory programs to achieve full implementation of the Animal Food Regulatory Program Standards (AFRPS) within five years. Eligible applicants, specifically state governments with established animal food safety programs, must maintain a good standing FDA inspectional contract and demonstrate compliance with federal regulations, with funding available through two tracks: the AFRPS Development Track, which provides up to $300,000 per year for new programs, and the AFRPS Maintenance Track, which offers tiered funding based on performance for established programs. This initiative is critical for advancing food safety and public health by fostering collaboration between state and federal regulatory bodies, with a total funding pool of $10.6 million available for fiscal year 2025. Interested parties can contact Danielle Head at danielle.head@fda.hhs.gov for further information, with applications due periodically between July 2025 and March 2027.
    Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives." This cooperative agreement aims to enhance the capabilities of State animal food regulatory programs to fully implement the Animal Feed Regulatory Program Standards (AFRPS) and to develop standardized processes that promote mutual reliance between federal and state regulatory efforts. The initiative is crucial for establishing a nationally integrated animal food safety system, ensuring that state programs can effectively manage animal food safety regulations. Interested organizations must meet specific eligibility criteria, including the ability to enter into a 20.88 information disclosure agreement with the FDA, and the funding amount is set at $10.6 million, with approximately 30 awards expected. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.
    Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) Clinical Trial Not Allowed
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity for the collection of long-term data on antimicrobial use in animals, with a focus on diverse sectors such as livestock, poultry, and companion animals. The primary objectives of this initiative are to gather comprehensive antimicrobial use data and to contribute to the development of data collection frameworks that support antimicrobial stewardship in veterinary settings. This funding is crucial for advancing the FDA's initiatives and the National Action Plan's goals to enhance understanding and management of antimicrobial use in animal agriculture. Interested small businesses can apply for a total estimated funding of $600,000, with an award ceiling of $200,000 per project, and are encouraged to contact Janelle Fundersburg at janelle.fundersburg@fda.hhs.gov or 301-798-2533 for further information.
    Collaborations to Enhance Drug Development and Regulatory Science
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Federal and State Integration Activities to Advance Cooperation and Regulatory Standards Among Animal Food Safety Regulatory Programs
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a cooperative agreement grant titled "Federal and State Integration Activities to Advance Cooperation and Regulatory Standards Among Animal Food Safety Regulatory Programs." This funding opportunity aims to enhance collaboration among national feed associations and state animal food safety regulatory programs, focusing on improving regulatory and surveillance protection programs and promoting the Animal Feed Regulatory Program Standards (AFRPS). The initiative is crucial for building a cohesive national animal food safety system through effective resource leveraging and inter-agency collaboration. Interested applicants, specifically national organizations and associations representing state animal food regulatory programs in partnership with higher education institutions, can reach out to Danielle Head at danielle.head@fda.hhs.gov for further information. The expected number of awards is one, with no cost-sharing requirement, and the opportunity is open for the fiscal year 2025.
    Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)." This initiative aims to support innovative natural history studies that generate high-quality data to advance medical product development for rare diseases with significant unmet needs. The funding is crucial for addressing knowledge gaps and facilitating the development of treatments in this area. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with grant amounts reaching up to $600,000. The application deadline is February 8, 2028, and interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov for further information.